文献速递呼吸衰竭与机械通气消化、代谢与肾脏急症

美国大样本中重症社区获得性肺炎的病因、治疗与结局

Etiology, Treatments, and Outcomes of Patients With Severe Community-Acquired Pneumonia in a Large U.S. Sample.
PubMed 文献 · Crit Care Med · 2022-02-22
一句话结论美国177家医院数据显示,符合指南重症标准的社区获得性肺炎患者死亡率22.0%、住院费用$20,046,但65%重症患者使用万古霉素、42.8%使用哌拉西林-他唑巴坦,广谱治疗普遍。

该回顾性观察性队列研究纳入美国177家医院154,799例成人肺炎患者,其中21,805例(14.1%)符合指南定义的重症社区获得性肺炎(sCAP)标准。sCAP患者器官衰竭评分更高(1.9 vs 0.63)、住院死亡率更高(22.0% vs 5.0%)、住院时间更长(8 vs 5天)、费用更高($20,046 vs $7,543),血培养阳性率(10.0% vs 4.5%)和呼吸道培养阳性率(34.2% vs 21.1%)均约为非重症患者的两倍,对一线CAP抗生素耐药的分离株更多(重症10% vs 非重症3.1%)。无论病情轻重,血培养最常见病原为肺炎链球菌,呼吸道最常见为金黄色葡萄球菌和假单胞菌属。尽管仅少数sCAP患者培养出耐药菌,65%接受了万古霉素、42.8%接受了哌拉西林-他唑巴坦,提示抗菌药物和诊断管理计划有较大改进空间。

要点

  • 154,799例肺炎患者中21,805例(14.1%)符合指南重症标准,其住院死亡率为22.0%,非重症为5.0%(p<0.001)。
  • sCAP患者器官衰竭评分1.9 vs 非重症0.63(p<0.001),住院时间8 vs 5天(p<0.001),费用$20,046 vs $7,543(p<0.001)。
  • sCAP患者血培养阳性率10.0% vs 非重症4.5%(p<0.001),呼吸道培养阳性率34.2% vs 21.1%(p<0.001)。
  • 对一线CAP抗生素耐药的分离株在重症中占10%,非重症中占3.1%(p<0.001)。
  • 尽管仅少数sCAP患者培养出耐药菌,65%接受了万古霉素、42.8%接受了哌拉西林-他唑巴坦。

适用人群与场景

  • 美国177家医院住院的成人(≥18岁)肺炎患者,主要诊断为肺炎,或次要诊断为肺炎且主要诊断为脓毒症或呼吸衰竭。
  • 比较符合至少一项指南定义的重症肺炎主要标准的患者与非重症患者。

处置流程与药物剂量

  • sCAP患者中65%接受万古霉素治疗。
  • sCAP患者中42.8%接受哌拉西林-他唑巴坦治疗。

研究设计与关键结果

  • 回顾性观察性队列研究,纳入美国Premier Healthcare Database中177家医院的154,799例成人肺炎患者。
  • 21,805例(14.1%)符合sCAP标准;sCAP患者器官衰竭评分1.9 vs 非重症0.63(p<0.001)。
  • sCAP住院死亡率22.0% vs 非重症5.0%(p<0.001);住院时间8 vs 5天(p<0.001);费用$20,046 vs $7,543(p<0.001)。
  • sCAP血培养阳性率10.0% vs 非重症4.5%(p<0.001);呼吸道培养阳性率34.2% vs 21.1%(p<0.001)。
  • 对一线CAP抗生素耐药的分离株:重症10% vs 非重症3.1%(p<0.001)。
  • 无论病情轻重,血培养最常见病原为肺炎链球菌,呼吸道最常见为金黄色葡萄球菌和假单胞菌属。
  • 尽管仅少数sCAP患者培养出耐药菌,65%接受万古霉素、42.8%接受哌拉西林-他唑巴坦。
  • 近所有肺炎患者接受血培养,四分之一非重症患者接受痰培养。

证据类型、等级与局限

  • 证据类型:回顾性观察性队列研究。
  • 局限:原文未报告局限性。

对床旁实践的改变

  • 本研究显示sCAP患者广谱抗菌药物使用普遍(65%万古霉素、42.8%哌拉西林-他唑巴坦),而耐药菌培养阳性者少,提示抗菌药物管理计划有改进空间。
  • 本研究显示近所有肺炎患者接受血培养、四分之一非重症患者接受痰培养,提示诊断管理计划有改进空间。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

OBJECTIVES: Compare the clinical practice and outcomes in severe community-acquired pneumonia (sCAP) patients to those in non-sCAP patients using guideline-defined criteria for sCAP.

DESIGN: Retrospective observational cohort study.

SETTING: One hundred seventy-seven U.S. hospitals within the Premier Healthcare Database.

PATIENTS: Hospitalized adult (≥ 18 yr old) patients with pneumonia.

MEASUREMENTS AND MAIN RESULTS: Adult patients (≥ 18 yr old) with a principal diagnosis of pneumonia or a secondary diagnosis of pneumonia paired with a principal diagnosis of sepsis or respiratory failure were included. Patients with at least one guideline-defined major criterion for severe pneumonia were compared with patients with nonsevere disease. Among 154,799 patients with pneumonia, 21,805 (14.1%) met criteria for sCAP. They had higher organ failure scores (1.9 vs 0.63; p < 0.001) and inpatient mortality (22.0 vs 5.0%; p < 0.001), longer lengths of stay (8 vs 5 d; p < 0.001), and higher costs ($20,046 vs $7,543; p < 0.001) than those with nonsevere disease. Patients with sCAP had twice the rate of positive blood cultures (10.0% vs 4.5%; p < 0.001) and respiratory cultures (34.2 vs 21.1%; p < 0.001) and more often had isolates resistant to first-line community-acquired pneumonia antibiotics (10% of severe vs 3.1% of nonsevere; p < 0.001). Regardless of disease severity, Streptococcus pneumoniae was the most common pathogen recovered from blood cultures and Staphylococcus aureus and Pseudomonas species were the most common pathogens recovered from the respiratory tract. Although few patients with sCAP had cultures positive for a resistant organism, 65% received vancomycin and 42.8% received piperacillin-tazobactam.

CONCLUSIONS: sCAP patients had worse outcomes and twice the rate of culture positivity. S. aureus and S. pneumoniae were the most common organisms in respiratory and blood specimens, respectively. Although only recommended for sCAP patients, nearly all pneumonia patients received blood cultures, a quarter of nonsevere patients received sputum cultures, and treatment with broad-spectrum agents was widespread, indicating fertile ground for antimicrobial and diagnostic stewardship programs.

来源:Crit Care Med,查看原文。版权归原作者所有。

参考来源

  1. Haessler S, Guo N, Deshpande A, et al. Etiology, Treatments, and Outcomes of Patients With Severe Community-Acquired Pneumonia in a Large U.S. Sample. Crit Care Med. 2022. PMID: 35191410. doi:10.1097/CCM.0000000000005498

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。